Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway

Oncology Reports

Volumn 16, Issue 6, 2006, Pages 1273-1276

  Issat, Tadeusz ^a   Jakóbisiak, Marek ^a   Golab, Jakub ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Berberine; Cholesterol; Mevalonate pathway

Indexed keywords

ANTINEOPLASTIC AGENT; BERBERINE; HYPOCHOLESTEROLEMIC AGENT; MEVALONIC ACID; MEVINOLIN;

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; TUMOR CELL LINE;

ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS; BERBERINE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOVASTATIN; MEVALONIC ACID;

EID: 34249941148     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.6.1273     Document Type: Article

References (28)

1. Kuo CL, Chi CW and Liu TY: The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203: 127-137, 2004.
2. Lin CC, Kao ST, Chen GW, Ho HC and Chung JG: Apoptosis of human leukemia HL-60 cells and murine leukemia WEHI-3 cells induced by berberine through the activation of caspase-3. Anticancer Res 26: 227-242, 2006.
3. Lin JP, Yang JS, Lee JH, Hsieh WT and Chung JG: Berberine induces cell cycle arrest and apoptosis in human gastric carcinoma SNU-5 cell line. World J Gastroenterol 12: 21-28, 2006.
4. Kang MR and Chung IK: Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine. Mol Pharmacol 61: 879-884, 2002. (Pubitemid 34273168)
5. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J and Jiang JD: Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344-1351, 2004. (Pubitemid 40022716)
6. Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S and Fujiwara H: Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells. J Ethnopharmacol 66: 227-233, 1999. (Pubitemid 29307925)
7. Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S and Fujiwara H: Inhibition of activator protein 1 activity by berberine in human hepatoma cells. Planta Med 65: 381-383, 1999. (Pubitemid 29249921)
8. Peng PL, Hsieh YS, Wang CJ, Hsu JL and Chou FP: Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol Appl Pharmacol 214: 8-15, 2006.
9. Mantena SK, Sharma SD and Katiyar SK: Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 5: 296-308, 2006.
10. Jakobisiak M and Golab J: Potential antitumor effects of statins (Review). Int J Oncol 23: 1055-1069, 2003.
11. Issat T, Nowis D, Jakobisiak M and Golab J: Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncol Rep 12: 1371-1375, 2004.
12. Kaminski R, Kozar K, Kopec M, Basak G, Skierski JS, Koronkiewicz M, Jakobisiak M and Golab J: Discussion on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 123: 1747-1748, 2002. (Pubitemid 35231674)
13. Fritz G: HMG-CoA reductase inhibitors (statins) as anticancer drugs (Review). Int J Oncol 27: 1401-1409, 2005.
14. Cohen JI: HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma. Br J Cancer 92: 1593-1598, 2005.
15. Golab J, Nowis D, Skrzycki M, Czeczot H, Baranczyk-Kuzma A, Wilczynski GM, Makowski M, Mroz P, Kozar K, Kaminski R, Jalili A, Kopec M, Grzela T and Jakobisiak M: Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem 278: 407-414, 2003. (Pubitemid 36043590)
16. Golab J, Stoklosa T, Czajka A, Dabrowska A, Jakobisiak M, Zagozdzon R, Wojcik C, Marczak M and Wilk S: Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res 20: 1717-1721, 2000. (Pubitemid 30628192)
17. Feleszko W, Balkowiec EZ, Sieberth E, Marczak M, Dabrowska A, Giermasz A, Czajka A and Jakobisiak M: Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81: 560-567, 1999. (Pubitemid 29203053)
18. Nowis D, Legat M, Grzela T, Niderla J, Wilczek E, Wilczynski GM, Glodkowska E, Mrowka P, Issat T, Dulak J, Jozkowicz A, Was H, Adamek M, Wrzosek A, Nazarewski S, Makowski M, Stoklosa T, Jakobisiak M and Golab J: Heme oxygenase-1 protects tumor cells against photodynamic therapymediated cytotoxicity. Oncogene 25: 3365-3374, 2006. (Pubitemid 43880305)
19. Jakobisiak M, Bruno S, Skierski JS and Darzynkiewicz Z: Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88: 3628-3632, 1991. (Pubitemid 21916676)
20. Keyomarsi K, Sandoval L, Band V and Pardee AB: Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51: 3602-3609, 1991.
21. Giermasz A, Makowski M, Kozlowska E, Nowis D, Maj M, Jalili A, Feleszko W, Wojcik C, Dabrowska A, Jakobisiak M and Golab J: Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer 97: 746-750, 2002. (Pubitemid 34106327)
22. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS and Gomez DE: Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50: 83-93, 1998. (Pubitemid 28438864)
23. Matar P, Rozados VR, Binda MM, Roggero EA, Bonfil RD and Scharovsky OG: Inhibitory effect of lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis 17: 19-25, 1999. (Pubitemid 29284560)
24. Jani JP, Specht S, Stemmler N, Blanock K, Singh SV, Gupta V and Katoh A: Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 13: 314-324, 1993.
25. Soma MR, Baetta R, De Renzis MR, Mazzini G, Davegna C, Magrassi L, Butti G, Pezzotta S, Paoletti R and Fumagalli R: In vivo enhanced antitumor activity of carmustine [N,N′-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res 55: 597-602, 1995.
26. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ and Guchelaar HJ: The risk of cancer in users of statins. J Clin Oncol 22: 2388-2394, 2004. (Pubitemid 41115396)
27. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK and Rennert G: Statins and the risk of colorectal cancer. N Engl J Med 352: 2184-2192, 2005. (Pubitemid 40727085)
28. Iizuka N, Hazama S, Yoshimura K, Yoshino S, Tangoku A, Miyamoto K, Okita K and Oka M: Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer 99: 286-291, 2002. (Pubitemid 34309488)